In a JAMA Network Open study, researchers found no evidence of neuroinflammation or blood-brain barrier dysfunction in cerebrospinal fluid markers of individuals with post-COVID-19 condition and neuropsychiatric symptoms compared to controls. The study, which assessed cytokines, chemokines, and neuroinflammation markers, suggests that persistent central nervous system immune activation may not be the primary driver of neurological long COVID symptoms.
Cognitive behavioral therapy boosts quality of life for young cancer patients
Many cancer patients struggle with their conditions by having negative thoughts, behaviors and emotions.
September 10, 2024